NeuroScientific Biopharmaceuticals clears key US Crohn’s trial hurdle
NeuroScientific Biopharmaceuticals has landed key US backing for its Phase 2 stem cell Crohn’s trial, green-lighting a planned year-end start subject to final preparations.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.smh.com.au — the content belongs to Sydney Morning Herald - Business.